doctor on phone - Referrals for Clinicians

How We Work With Healthcare Providers

How We Work With Healthcare Providers

In our experience, patients are best served when the all members of the provider team work together and are fully informed. We value your expertise and welcome the opportunity to support you and your patients.

Submit your referral
maxresdefault - Referrals for Clinicians

We Work With:

  • Psychiatrists
  • Therapists
  • Psychologists
  • Neurologists
  • Pain Specialists
  • Primary Care Physicians
  • Coaches
  • Social Workers

Treatments for:

  • Depression
  • Anxiety
  • PTSD
  • Migraines & Headaches
  • CRPS & Chronic Pain
  • Immunity & Resilience

Our Services:

  • IV Ketamine
  • Spravato (intranasal Ketamine)
  • Stellate Ganglion Blocks (SGB)
  • IV Nutrients & Vitamins
  • IV NAD+
  • IV Glutathione
  • Ketamine Assisted Psychotherapy (KAP)
  • Life Skills Coaching

Let us help you support your patients!

We pride ourselves on offering our patients a process that is administratively efficient and clinically rigorous while maintining a high level of personalized care and attention.

Step 1: Confirm Your Patient's Interest

The first step is to confirm your patient's openness/interest in infusion therapies such as Ketamine, NAD+, Vitamins, Glutathione, etc. by having a conversation with the differences between Combination Infusion Therapy and conventional approaches to treating anxiety, depression and PTSD.

Step 2: Submit Online Patient Referral Form

If you believe your patient may be a good fit for guided Ketamine treatments, then please tell us a little about them so we may contact them. You can submit a Patient Referral Form here.

Step 3: Review Patient Care Plan With Us

Once we have spoken with your patient and received required documents, we will contact you to confirm/discuss our treatment plan. We value your input and experience and will work closely with you to ensure the best patient care possible.

Step 4: We Provide Ongoing Updates About Treatments and Progress

With your patient's consent, we will share treatment information with you in order to keep you informed of their progress.

Research Papers

Comparative Efficacy of Racemic Ketamine and Esketamine for Depression

February 15, 2021

Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.

Read More

Ketamine Use for Cancer and Chronic Pain Management

February 2, 2021

Clayton Culp, Hee Kee Kim and Salahadin Abdi Published 2 February 2021 | https://doi.org/10.3389/fphar.2020.599721 Abstract […] Read More

Antidepressant Actions of Ketamine Engage Cell-Specific Translation via eIF4E

December 16, 2020

Sub-anaesthetic doses of ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist provide rapid and long-lasting antidepressant effects in these patients, but the molecular mechanism of these effects remains unclear.

Read More

The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research

November 23, 2020

Hartej Gill, Barjot Gill, Nelson B. Rodrigues, Orly Lipsitz, Joshua Daniel Rosenblat, Sabine El-Halabi, Flora […] Read More

A Proof-of-Concept Study of Subanesthetic Intravenous Ketamine Combined With Prolonged Exposure Therapy Among Veterans With Posttraumatic Stress Disorder

November 10, 2020

Paulo R. Shiroma, MD; Paul Thuras, PhD; Joseph Wels, MD; Christopher Erbes, PhD; Shannon Kehle-Forbes, […] Read More

Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies

July 29, 2020

Camilla Crisanti, Paolo Enrico, Alessio Fiorentini, Giuseppe Delvecchio, Paolo Brambilla Published 29 July 2020 |  […] Read More

The emergence of ketamine as a novel treatment for posttraumatic stress disorder

June 19, 2020

Adriana Feder, Sarah B. Rutter, Daniela Schiller, Dennis S.Charney Published 19 June 2020 | https://doi.org/10.1016/bs.apha.2020.05.004 […] Read More

Ketamine Can Reduce Harmful Drinking by “Rewriting” Your Memories

June 11, 2020

Maladaptive reward memories (MRMs) are involved in the development and maintenance of acquired overconsumption disorders, such as harmful alcohol and drug use. Here we demonstrate that the N-methyl D-aspartate (NMDA) antagonist ketamine is able to disrupt MRMs in hazardous drinkers when administered immediately after their retrieval.

Read More
Scroll to Top